A tool to help you decide about Prep in Alabama and Botswana
Part of Immune system & allergy, Infections clinical trials.
This study tests a decision-support tool that helps people decide whether to use PrEP, a daily pill that prevents HIV, and helps clinics support that choice. It is for young adults in Alabama and Botswana, as well as clinic staff and policy makers, and aims to make it easier to start and stay on PrEP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You cannot be HIV positive.
- You are either someone who takes or is eligible for PrEP (a daily pill that prevents HIV) in Alabama, OR you joined the earlier Tshireletso study in Botswana.
- You might also qualify if you work as a PrEP provider, clinic administrator, policy maker, or program leader at an outpatient clinic.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a program to help Black women decide whether to start PrEP (a daily pill that prevents HIV). It aims to make it easier to get PrEP and support your health.
This trial tests a “one-stop” support pathway meant to make it easier for PrEP clinics in Kenya to deliver PrEP care. It involves interviews with people using PrEP services and with healthcare and policy leaders who help run or guide PrEP delivery.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
This study tests a counseling program to help women decide whether to use PrEP (a daily pill that prevents HIV). It aims to make PrEP choices easier and more informed in sexual and reproductive health clinics.
This study tests a simple online tool to help young people decide whether PrEP (a daily pill that prevents HIV) might be right for them. The tool uses information from an at-home HIV test and is designed to make PrEP information easier to understand.
This study is testing a decision-support tool that helps emergency department patients learn about and start taking PrEP, a daily medicine that prevents HIV. If you are HIV negative and visiting the ER for a non-life-threatening issue, this study may help you access HIV prevention.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.